Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (704)	11/10/1999 9:46:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 1494

"The Company expects to report data from this important trial by the end of 1999." check the September 14, 1999 news item. Probably the details are out somewhere, or the vascular dementia Merz trials to be presented sooner than expected, and also someone knows, or just speculation that the time is near. And in the last pr news: " NTI(R) recently announced the completion of enrollment of the 421-patient Phase IIB Memantine trial in diabetic neuropathy. The results of this trial are currently being analyzed and will be announced in December." (I think they mean December, 1999, combining the two pieces of news). The last one is more specific, either someone knows, or it will be earlier, or a new financing, or just plain positioning speculation base on the pre-announced timing of results release.